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Cyclic Arginine-Glycine-Aspartate Peptides Enhance
Three-Dimensional Stem Cell Osteogenic Differentiation
Susan X. Hsiong, Ph.D.,1,2 Tanyarut Boontheekul, Ph.D.,3
Nathaniel Huebsch, B.S.,2,4 and David J. Mooney, Ph.D.2
The role of morphogens in bone regeneration has been widely studied, whereas the effect of matrix cues, par-
ticularly on stem cell differentiation, are less well understood. In this work, we investigated the effects of arginine-
glycine-aspartate (RGD) ligand conformation (linear vs cyclic RGD) on primary human bone marrow stromal cell
(hBMSC) and D1 stem cell osteogenic differentiation in three-dimensional (3D) culture and compared their re-
sponse with that of committed MC3T3-E1 preosteoblasts to determine whether the stage of cell differentiation
altered the response to the adhesion ligands. Linear RGD densities that promoted osteogenic differentiation of
committed cells (MC3T3-E1 preosteoblasts) did not induce differentiation of hBMSCs or D1 stem cells, although
matrices presenting the cyclic form of this adhesion ligand enhanced osteoprogenitor differentiation in 3D culture.
This may be due to enhanced integrin–ligand binding. These studies indicate that biomaterial design parameters
optimized for differentiated cell types may not directly translate to stem cell populations, because less-committed
cells may require more instruction than differentiated cells. It is likely that design of synthetic extracellular
matrices tailored to promote stem cell differentiation may enhance bone regeneration by transplanted cells.
Introduction
Bone tissue engineering is a new therapeutic approachthat aims to regenerate or repair bone tissue using scaf-
folds, cells, and inductive factors to actively stimulate tissue
formation.1–5 Isolation of sufficient numbers of primary hu-
man osteoblasts is difficult because it requires sacrifice of
healthy bone tissue, and this has stimulated interest in the
use of osteoprogenitor cells as a source for bone regenera-
tion. Because these multipotential precursor cells are self-
renewing, maintain their differentiation ability, and can be
readily expanded in culture, stem cells have great potential for
clinical utility to repair or regenerate tissues.6 Unlike embry-
onic stem cells, which have the capability to recapitulate all
the tissues of the body (e.g., cells derived from all three germ
layers), adult stem cells are more limited in their differentia-
tion capability. However, it is likely that adult stem cells will
have greater clinical utility in the near future, because the
application of these cells for autologous therapies is straight-
forward. Derived from the peripheral blood, bone marrow,
muscle, and even adipose tissue, adult progenitor cells can be
expanded in culture and induced down a specific lineage to
form mature, differentiated cells that can be used to repair or
regenerate tissue.7 There are more than 800 clinical trials
currently investigating the use of human adult stem cells for
the treatment of a variety of diseases,8 and it is likely that, in
many situations, the effective use of stem cells will require a
synthetic extracellular matrix (ECM) analog to tightly regulate
their fate.
The majority of clinical studies using adult stem cells to
regenerate bone have focused on localized delivery via scaf-
folds to provide site-specific delivery of large quantities of
cells.9–11 A variety of synthetic and natural materials have
been investigated as synthetic ECMs (sECMs) to deliver
the cells. Furthermore, these scaffolds may allow control of
the specific microenvironment and strongly influence cell
behavior and clinical outcomes.12 Many studies have focused
on the delivery of signaling molecules such as growth factors
for bone regeneration, whereas the effect of matrix cues,
particularly on stem cell differentiation, is less well under-
stood.13–15 However, presentation of appropriate adhesion
cues may be critical, because growth factor delivery without
optimal scaffold properties has failed in some studies to in-
duce significant bone formation.16
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The presentation of adhesion ligands from sECMs provides
an attractive approach to regulate osteoprogenitor cell dif-
ferentiation. Matrix cues that enhance cell differentiation
in vitro have been demonstrated to correlate with enhanced
bone regeneration in vivo,17 suggesting that in vitro studies
with appropriate model systems can provide useful data for
design of cell transplantation vehicles. Alginate hydrogels
provide a useful model sECM for these types of studies, be-
cause alginate is a well-characterized material with good
biocompatibility and low toxicity, and its gels have a highly
hydrated polymer network similar to native ECMs.18 Alginate
gels have previously been used to study cell–matrix interac-
tions in vitro and in vivo, are extensively used as a cell im-
mobilization and transplantation material,16,17,19,20 and can be
covalently modified with arginine-glycine-aspartate (RGD)
peptide sequences commonly found in ECM proteins
(e.g., collagen, fibronectin, vitronectin) using standard carbo-
diimide chemistry.21
This study addressed the hypothesis that sECMs presenting
cyclic RGD sequences to encapsulated cells would enhance
osteoprogenitor differentiation better than linear RGD se-
quences. The native conformation of the RGD sequence found
in ECM proteins such as bone sialoprotein (BSP) is a loop
conformation,22 and cyclic RGD-presenting peptides have
higher binding affinity and selectivity than linear peptides.23,24
To address the hypothesis, alginate hydrogels were modified
with the linear RGD peptide sequence (glycine4-arginine-
glycine-aspartate-serine-proline (G4RGDSP)) or the cyclic
RGD peptide (glycine4-cystine-arginine-glycine-aspartate-
serine-proline-cystine (G4CRGDSPC)). The osteoprogenitors
employed in these studies were primary human bone marrow
stromal cells (hBMSCs), a heterogeneous cell population con-
sisting of cells at various stages of differentiation, and the
clonally derived mouse bone marrow stromal D1 cell line.25
BMSCs are useful for clinical applications, but the use of a
homogenous cell population may be better suited for exam-
ining how ECM cues influence stem cell fate while eliminating
effects due to the presence of other progenitor cell types. D1
stem cells are multipotent and have been demonstrated to
differentiate toward adipocytes, chondrocytes, and osteo-
blasts.26–28 D1 cells also express osteocalcin and type I collagen
(a1)2a2 messenger RNA (mRNA), as well as high levels of al-
kaline phosphatase (ALP) and matrix mineralization in vitro.25
We investigated the effects of RGD ligand presentation on
primary hBMSC and D1 stem cell osteogenic differentiation in
three-dimensional (3D) culture and compared the cell response
with that of committed MC3T3-E1 preosteoblasts to determine
whether the stage of cell differentiation altered the response
to the adhesion ligands.
Materials and Methods
Cell culture
Murine preosteoblast MC3T3-E1 cells, a generous gift
from Dr Renny Franceschi (University of Michigan, Ann
Arbor MI) were cultured in alpha minimum essential me-
dium (a-MEM) (without ascorbic acid, Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS, In-
vitrogen) and 100 units=mL penicillin-streptomycin (PS, In-
vitrogen) at 378C and 5% carbon dioxide (CO2). A mouse
clonally derived BMSC line (D1 stem cells,25 ATCC, Mana-
ssas, VA) was cultured in Dulbecco’s modified Eagle me-
dium (DMEM; ATCC) supplemented with 10% FBS (ATCC)
and 100 units=mL PS.
hBMSCs were isolated from bone marrow aspirate ob-
tained from NDRI (Philadelphia, PA) using Ficoll-Paque (GE
Healthcare, Piscataway, NJ) per the manufacturer’s instruc-
tions. Cells at the low-density interphase were collected,
rinsed twice with phosphate buffered saline (PBS), and
transferred to tissue culture flasks. hBMSCs were cultured in
a-MEM containing 10% FBS and 1% PS. Cells were left un-
perturbed for 1 week to allow the adherent cell fraction to
adhere and proliferate. After 1 week, fresh culture medium
was added, and cells were fed every 2 to 3 days thereafter
until further passaging. All hBMSCs used in these studies
were from the same donor (18-year-old male) and used at
passage 5 and below.
For osteogenic characterization of D1 cells, cells were see-
ded into 12-well tissue culture plates at 5000 cells=cm2 and
cultured in serum containing DMEM supplemented with
50 mg=mL ascorbic acid and 10 mM b-glycerophosphate for 3
weeks. For osteogenic characterization of hBMSCs, cells were
cultured in a-MEM supplemented with 50 mg=mL ascorbic
acid, 10 mM b-glycerophosphate, and 0.1 mM dexamethasone
(Sigma, St. Louis, MO). The state of differentiation was ana-
lyzed by quantifying ALP activity and osteocalcin secretion
and staining for mineral deposition (von Kossa).
For adipogenic characterization of D1 stem cells, cells were
cultured in DMEM containing 10% FBS and 1% PS supple-
mented with 10–7 M dexamethasone. For adipogenic charac-
terization of hBMSCs, cells were cultured in Poietics
adipogenic maintenance (containing insulin) and induction
(containing insulin, dexamethasone, indomethacin, and 3-
isobutyl-1-methyl-xanthine, as described from manufacturer)
media for three cycles of induction and maintenance (Lonza
Bioscience, Inc., Basel, Switzerland). Cells undergoing adi-
pogenic induction were stained with Oil Red O for lipid
vacuoles.
For chondrogenic characterization of D1 stem cells and
hBMSCs, cells were pelleted in a 15-mL conical tube and
cultured as cell pellets with DMEM containing 10% FBS and
1% PS supplemented with 10 ng=mL transforming growth
factor beta-1 (TGF-b1; R&D Systems, Minneapolis, MN) for 14
days. Cells pellets were harvested, fixed, paraffin embedded,
sectioned (5-mm-thick sections), and analyzed for glycosami-
noglycans using Safranin O staining.
The DNA content of the samples was determined using
the Hoechst 33258 DNA dye assay using calf thymus as a
standard. An equal volume (50–100 mL) of Caron’s lysis
buffer (0.025 M tris hydrochloric acid (HCl), 0.4 M sodium
chloride, 0.5% sodium dodecyl sulfate, adjusted to pH 7.4)
was added to the cell lysates and sonicated for 4 to 5 seconds
before DNA analysis.
Reverse transcription polymerase chain reaction
For reverse transcription polymerase chain reaction (RT-
PCR) of D1 cells encapsulated in alginate gels (3D culture),
samples were dissolved in 50 mM ethylenediaminetetraacetic
acid (EDTA) in PBS for 30 minutes at 48C to release the en-
capsulated cells. Upon centrifugation (at 400 g) and aspiration
of the EDTA solution, RNA was isolated from samples using a
RNeasy mini kit (Qiagen, Valencia, CA). RNA was quantified
using the Nanodrop (Nanodrop Technologies, Wilmington,
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DE) and analyzed using the Bioanalyzer RNA Nano kit
(Agilent Technologies, Inc., Santa Clara, CA). One mg of each
RNA sample was reverse transcribed to complementary DNA
(cDNA) in a 50-mL reaction using the high-capacity cDNA
archive kit (Applied Biosystems, Foster City, CA). The PCR
reaction performed using the primers for osteocalcin and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; In-
vitrogen) and the HotStarTaq Plus PCR kit (Qiagen) using a
MJ Tetrad Thermal Cycler (Bio-Rad, Hercules, CA). Cycling
conditions were 5 min activation at 958C, 1 min denaturation
at 948C, 1 min annealing at 608C, 1 min extension at 728C for
35 cycles, and a final extension for 10 min at 728C. Primer







Peptide-modified alginate was prepared using standard
carbodiimide chemistry as described previously21 from Ul-
trapure MVG, molecular weight 270,000 g=mol (Pronova,
Oslo, Norway) alginate and linear G4RGDSP or cyclic
G4CRGDSPC peptide for certain studies (Peptides Interna-
tional, Inc., Louisville, KY). The overall number or density of
RGD peptides covalently conjugated to alginate polymer was
varied by altering the concentration of RGD peptide em-
ployed in the carbodiimide reaction and the correlation be-
tween the number of coupled RGD peptide, and the input
concentration has previously determined.21 Although not
measured directly, the coupling efficiency of the cyclic pep-
tide would be expected to be similar to that of the linear RGD
peptide, because the carbodiimide reaction for peptide con-
jugation occurs between the carboxy groups on the alginate
polymer chain and the terminal amine of the peptides, and the
sequence of the two peptides is similar (linear G4RGDSP,
cyclic G4CRGDSPC). We have confirmed that the conjugation
chemistry maintains the cyclic nature of the cyclic RGD pep-
tide (absence of free thiols) as assessed qualitatively using the
5,50-dithiobis(2-nitrobenzoate (DTNB) assay. Briefly, DTNB
solution was added to tubes containing alginate only, cyclic
RGD-modified alginate, cyclic RGD peptide (negative con-
trol), and denatured cyclic RGD peptide (exposing free thiols,
positive control). No colorimetric change was observed in the
cyclic RGD peptide or cyclic RGD peptide–modified alginate
condition (data not shown), indicating that the cyclic RGD
peptide–modified alginate maintained its cyclic structure.
The number of RGD peptides per alginate chain is
termed the degree of substitution (DS), with DS 1 defined as
one RGD peptide per alginate polymer chain, etc. Alginates
were reconstituted in a-MEM containing 1% PS to make a 2%
hydrogel solution. All chemicals were obtained from Sigma-
Aldrich (St. Louis, MO) unless otherwise noted. Alginate
hydrogel disks were ionically cross-linked using calcium
sulfate slurry in a 25:1 molar ratio before being cast between
glass plates. Disks (10 mm in diameter, 1 mm thick) were
made using an arch punch (McMaster-Carr, Atlanta, GA) and
maintained in a-MEM with 1% PS. Alginate hydrogel beads
(*1 mm diameter) were formed using ionic cross-linking of
alginate solution in a 0.1-m calcium chloride bath.17
Cell proliferation on alginate
Cells were seeded onto alginate disks at a seeding density
of 10,000 cells=cm2 and allowed to adhere for 5 h. Disks were
then transferred to new plates, and fresh medium was added.
At 5 h and days 1, 2, and 4, disks were transferred to 15-mL
tubes containing 1 mL of trypsin (Invitrogen) and incubated
for 5 min (378C), and 50 mM EDTA=PBS (pH 7.4) was added
to each tube to dissolve the disks. Cell counts from the solu-
tion were obtained using a Z2 Coulter Counter (Beckman
Coulter, Fullerton, CA). Quadruplicate samples were assayed
for each condition. Growth rates were calculated from cell
counts comparing cell numbers at day 5 with cell numbers 5 h
postseeding.
3D differentiation studies
Cells were encapsulated in 2% peptide-modified alginate
hydrogels at a concentration of 20106 cells=mL alginate (D1
cells) or 15106 cells=mL alginate (primary hBMSCs) using
uniform mixing. The cell–alginate solution was formed into
disks (as previously described) for D1 cells and beads (ap-
proximately 1 mm in diameter)30 for hBMSCs. Alginate beads
were cultured in 100-mL spinner flasks, and alginate disks
were cultured in a 24-well tissue culture plate (one well
per disk) on an orbital shaker (operating at approximately
84 rpm) at 378C and 5% CO2. DMEM was changed every 2
days and supplemented with 50 mg=mL ascorbic acid and
10 mM b-glycerophosphate (Sigma) with or without 10 ng=
mL BMP-2 for D1 cells or a-MEM (Invitrogen) supplemented
with 50 mg=mL ascorbic acid, 10 mm b-glycerophosphate, and
0.1 mM dexamethasone (Sigma) for hBMSCs.
At each time-point, 1 mL of fresh medium (without sup-
plements) was added to each sample, and the plate was placed
on an orbital shaker (operating at approximately 84 rpm)
overnight at 378C. Medium was collected and frozen for os-
teocalcin analysis. Cells were lysed in passive lysis buffer
(Promega, Madison, WI), and lysates were frozen for ALP and
DNA analysis. Samples were dissolved in 50 mM EDTA in
PBS for 30 min at 48C to release the encapsulated cells. Upon
centrifugation (at 400 g) and aspiration of the EDTA solution,
the cell pellet was rinsed once with PBS and then lysed with
150mL passive lysis buffer (Promega). Cell lysates were then
frozen and used for ALP and DNA analysis.
Osteogenic assays
ALP activity was quantified using a method based on
Lowry et al.31 Cell lysates were collected in passive lysis
buffer (Promega), and a portion was assayed with 50 mM p-
nitrophenyl phosphate in 100 mM glycine and 1 mM magne-
sium chloride at 378C. The absorbance of the p-nitrophenol
product from the reaction was read at 405 nm on a microplate
reader (BioTek Synergy HT, Winooski, VT). The enzyme ac-
tivity (expressed in of nmol of p-nitrophenol=min) was cal-
culated based on serially diluted p-nitrophenol standards and
normalized to total DNA content.
Osteocalcin synthesis was assayed using a mouse osteo-
calcin enzyme-linked immunosorbent assay kit, per the
manufacturer’s instructions (Biomedical Technologies, Inc.,
Stoughton, MA). The calcium content of cell lysates was as-
sayed by dissolving cultures with 1 M HCl and analyzing
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them using a calcium kit (Wako Pure Chemical, Osaka, Japan)
according to the manufacturer’s instructions.
For von Kossa staining, cell layers were fixed in 70%
ethanol, and a 5% silver nitrate solution was applied to the
cell layer and exposed to light for 15 min. Unreacted silver
nitrate was removed by addition of 5% sodium thiosulfate.
Cell layers were rinsed several times in PBS before obtaining
images with an Olympus IX81 inverted microscope (Mel-
ville, NY).
Statistical analysis
Statistical significance of data was assessed using one-way
analysis of variance with respect to conditions for the re-
spective experiment (varying culture medium supplements
or RGD ligand presentation), followed by a post hoc com-
parison using the Tukey test.
Results
Stem cell characterization
The multipotential differentiation capabilities of primary
hBMSCs and the clonally derived D1 cell line toward adipo-
genic, chondrogenic, and osteogenic lineages have been
previously described.32,33 In these studies, the adipogenic,
chondrogenic, and osteogenic differentiation of hBMSCs and
D1 cells was first assessed to confirm that the cells used in our
experiments maintained their multipotential capability. D1
cells cultured in adipogenic induction conditions for 3 weeks
stained positively for Oil Red O, indicating the presence of
lipid vacuoles (Fig. 1A). Under chondrogenic induction con-
ditions (micromass pellet culture for 2 weeks in medium
supplemented with 10 ng=mL TGF-b1), both cell types stained
positively with Safranin-O (Fig. 1B), indicating the presence of
glycosaminoglycans typical of a cartilage matrix. hBMSCs
and D1 cells also stained positively for von Kossa under os-
teogenic induction conditions (serum containing medium
supplemented with 50mg=mL ascorbic acid and 10 mM b-
glycerophosphate, with the addition of 0.1 mM dexametha-
sone for hBMSCs), indicative of matrix mineralization (Fig.
1C). Thus, the hBMSCs and D1 cells used in these studies are
both multipotential cell populations capable of forming car-
tilage, fat, and bone.
After defining culture conditions for the osteogenic differ-
entiation of D1 cells and hBMSCs, DNA content and ALP and
osteocalcin expression were quantified in the same, standard
2D culture system (tissue culture plastic). Osteogenic supple-
ments (50mg=mL ascorbic acid and 10 mM b-glycerophosphate)
enhanced the proliferation (Fig. 2A), ALP activity (Fig. 2B),
and osteocalcin synthesis (Fig. 2C) of murine D1 cells. ALP
activity of preosteoblasts, osteoblasts, and BMSCs typically
increases between 7 and 14 days of culture during active
matrix synthesis; then ALP activity decreases as osteocalcin
levels increase and matrix calcification occurs.34–36 As shown
in Figure 2B, ALP levels for the osteogenic supplement con-
dition peaked at day 7 and then decreased, indicating matrix
FIG. 1. Multipotential differentiation of primary human bone marrow stromal cells (hBMSCs) (first row) and D1 stem cells
(second row). Cells were cultured in adipogenic (A), chondrogenic (B), and osteogenic (C) conditions to assess the capability of
these multipotential cells to exhibit markers typical of adipocytes, chondrocytes, and osteoblasts, respectively. For adipogenic
conditions, cells were cultured for 21 days and stained with Oil Red O for lipid vacuoles (red). hBMSCs were counterstained
with hematoxylin (blue), whereas D1 cells (A, 2nd row) were not. For chondrogenic conditions, cell pellets were cultured for 14
days in medium supplemented with 10 ng=mL transforming growth factor beta-1. Cell pellets were fixed, sectioned, and
stained with Safranin-O for detection of glycosaminoglycans. To assess osteogenic differentiation, cells were cultured in
complete medium supplemented with 50 mg=mL ascorbic acid and 10 mM b-glycerophosphate and with (hBMSC) or without
(D1 cells) 0.1 mM dexamethasone and subjected to von Kossa staining to highlight mineral formation (day 21).
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synthesis earlier than in the medium-only condition. Osteo-
genic supplements promoted matrix synthesis as indicated by
the ALP activity in the medium-only condition not peak-
ing until much later. Serum-containing a-MEM with os-
teogenic supplements (50mg=mL ascorbic acid, 10 mM
b-glycerophosphate, and 0.1 mM dexamethasone) also en-
hanced proliferation (Fig. 3A), ALP activity (Fig. 3B), and
osteocalcin synthesis (Fig. 3C) of hBMSCs. ALP activity is
similar to reported values of hBMSCs under osteogenic cul-
ture conditions.34 These results all together indicate that D1
cells and hBMSCs undergo osteogenic differentiation and
express osteogenic markers typical of osteoblasts when cul-
tured under standard 2D conditions (tissue culture plastic).
3D differentiation of hBMSCs and D1 cells
To determine how RGD ligand presentation influenced the
differentiation of progenitor cells, D1 cells and hBMSCs were
encapsulated in alginate hydrogels modified with linear RGD
(degree of substitution [DS] 1, defined as one RGD peptide
per alginate polymer chain or overall linear RGD density of
6.25 mg=g alginate) and cultured for 3 weeks under dynamic
culture conditions (spinner flask or orbital shaker [84 rpm]) in
medium-containing osteogenic supplements. Osteocalcin was
the primary marker examined to assess stem cell osteogenic
differentiation because it is a late-stage, bone-specific marker
and is widely used to assess osteogenic differentiation of stem
cells. It has been previously demonstrated that RGD-modified
alginate conditions that promoted osteoblast differentiation
in vitro (as assessed according to osteocalcin secretion) also
correlated with enhanced bone tissue formation.17
Although MC3T3 preosteoblasts readily differentiated to-
ward osteoblasts, as assessed according to osteocalcin secre-
tion (Fig. 4A), D1 stem cells produced minimal osteocalcin
protein (Fig. 4B) under these conditions. Doubling the ligand
density from DS 1 to DS 2 (overall linear RGD density of
12.5 mg=g alginate) did not promote osteocalcin synthesis
in D1 cells either (data not shown). Because no osteocalcin
FIG. 2. Osteogenic characterization of D1 stem cells on
tissue culture plastic. DNA content (A), alkaline phosphatase
activity (B), and osteocalcin (C) of D1 cell lysates over time
when cultured in tissue culture plastic in Dulbecco’s modi-
fied Eagle medium alone (open circle) or with osteogenic
supplements (solid circle) (50mg=mL ascorbic acid, 10 mM b-
glycerophosphate). *p< 0.05 between noted conditions (me-
dium vs osteogenic supplements) at the same time-point.
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protein secretion was detected in D1 cells encapsulated in
unmodified alginate and DS 2 linear RGD-modified alginate
(Fig. 4B), osteocalcin gene expression of the encapsulated D1
cells was investigated. DS 2 linear RGD–modified alginate
slightly up-regulated osteocalcin mRNA of the encapsulated
D1 stem cells (Fig. 4C) but was insufficient to drive significant
differentiation (e.g., high levels of osteocalcin protein syn-
thesis). Similarly, primary hBMSCs encapsulated in DS 2
linear RGD alginate gels also failed to undergo osteogenic
differentiation as assessed according to osteocalcin protein
secretion (data not shown); osteocalcin mRNA was not eval-
uated. All together, these results indicated that matrix cues
that successfully induced differentiation of committed pre-
osteoblasts did not drive differentiation of the more-primitive
stem cells.
We hypothesized that the presentation of adhesion ligand
sequences with greater affinity may promote the proliferation
and differentiation of osteoprogenitors, because the modifi-
cation of materials with cyclic RGD peptides has been re-
ported to stimulate osteoblast adhesion, proliferation, and
bone formation.37,38 Although DS 2 cyclic RGD–modified al-
ginate substrates did not significantly enhance the adhesion,
spreading, or proliferation of D1 stem cells in 2D culture, the
hBMSC growth rate was almost three times as high on DS 2
cyclic RGD– as on DS 2 linear RGD–presenting substrates in
this condition (Fig. 5A). Furthermore, the higher-affinity li-
gand sequence also increased the cell spreading area of pri-
mary hBMSCs 5 h postseeding (data not shown).
To determine whether a higher-affinity ligand sequence
would promote differentiation of stem cells in 3D culture,
D1 cells and hBMSCs were encapsulated in cyclic RGD–
presenting alginate matrices in the presence of osteogenic
supplements. DS 2 cyclic RGD–modified alginate significantly
up-regulated the osteocalcin synthesis in D1 stem cells (Fig.
5B) and primary hBMSCs (Fig. 5C), whereas an alginate gel
presenting the same molar ratio of the linear RGD ligand did
not up-regulate osteocalcin secretion (Fig. 4B [D1 cells], hBMSC
osteocalcin protein data not shown). Encapsulated D1 cells and
FIG. 3. Osteogenic characterization of primary human bone
marrow stromal cells (hBMSCs) on tissue culture plastic.
DNA content (A), alkaline phosphatase activity (B), and os-
teocalcin (C) of primary hBMSC lysates over time when cul-
tured in tissue culture plastic in alpha minimum essential
medium alone (open circle, hatched bar) or medium with
osteogenic supplements (solid circle, filled bar) (50 mg=mL
ascorbic acid, 10 mM b-glycerophosphate, and 0.1mm dexa-
methasone). Values represent means and standard deviations
(n¼ 4). *p< 0.05 between noted conditions (medium vs oste-
ogenic supplements) at the same time-point.
268 HSIONG ET AL.
hBMSCs were viable throughout the culture period, as assessed
according to the quantitative tetrazolium compound assay
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS), inner salt; Cell-
Titer 96 Aqueous Nonradioactive Cell Proliferation Assay,
Promega, Madison, WI) or 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT) bromide staining, respectively.
Linear and cyclic RGD–modified alginates enhanced cell vi-
ability over unmodified alginate gels for both cell types (data
not shown).
Discussion
It is widely reported that hBMSCs undergo differentiation
toward multiple lineages,32,39 and the multipotential capa-
bility of the primary hBMSCs used in these studies and a
clonally derived murine bone marrow cell line (D1 cells) was
confirmed by culturing these cells under conditions that in-
duced differentiation toward bone, fat, and cartilage, because
the cells stained positive for markers typical of osteoblasts,
adipocytes, and chondrocytes. Supplements that induced
osteogenic differentiation of both cell types included ascorbic
acid and b-glycerophosphate, which are essential for matrix
synthesis.40 Although dexamethasone enhanced osteogenic
differentiation and matrix mineralization of hBMSCs, it in-
hibited differentiation and matrix mineralization of murine
D1 cells (data not shown). Dexamethasone has also been re-
ported to decrease mineralization and osteocalcin mRNA in
MC3T3-E1 preosteoblasts.41 Differences in the species of ori-
gin and stage of differentiation influence cell response to
signaling molecules42 and may have contributed to the ob-
served differences in hBMSC and D1 cell response to dexa-
methasone and BMP-2.
Alkaline phosphatase and osteocalcin secretion from
hBMSCs and D1 stem cells under osteogenic induction con-
ditions in tissue culture were similar in magnitude to those
reported for MC3T3 preosteoblasts in standard 2D culture35,36
but not in 3D culture in alginate hydrogels that presented
linear peptides. Osteocalcin secretion was negligible in os-
teoprogenitors maintained in 3D culture, whereas osteocalcin
synthesis in MC3T3 preostoblasts remained high in similar
culture conditions. RGD-modified alginate (DS 2 linear) up-
regulated osteocalcin mRNA levels in D1 stem cells but were
insufficient to induce significant osteocalcin secretion.
Progenitor cells encapsulated within gels presenting a
higher-affinity RGD sequence (cyclic RGD instead of linear
RGD peptide) promoted differentiation of D1 stem cells and
primary hBMSCs. Peak osteocalcin values for both cell types
were approximately 2 ng=day per mg of DNA, similar to those
reported for MC3T3 preosteoblasts and primary murine os-
teoblasts.35,36 Furthermore, osteogenic differentiation of stem
cells within DS 2 cyclic RGD alginate did not require growth
factors, such as BMP-2. However, it is possible that additional
FIG. 4. Differentiation of MC3T3 (A) and D1 cells (B) in
three-dimensional culture. Cells were encapsulated in linear
arginine-glycine-aspartate (RGD)-modified alginate (dia-
mond) (degree of substitution [DS] 1, equivalent to 1 mole of
RGD per mole of alginate and total linear RGD density of
6.25 mg RGD=g alginate) or unmodified alginate (open
square). (A) MC3T3 osteocalcin secretion (normalized to
DNA) assessed at days 3, 10, and 21 of culture. (B) D1 os-
teocalcin secretion and osteocalcin messenger RNA levels (C)
at days 3, 10, and 21 of culture. Cells were cultured at 378C
and 5% carbon dioxide for 21 days, and medium was sup-
plemented with 50mg=mL ascorbic acid only for osteogenic
induction of MC3T3s and 50mg=mL ascorbic acid and 10 mM
b-glycerophosphate for D1 cells. Values represent means and
standard deviations (n¼ 4). *p< 0.05 between noted condi-
tions (unmodified vs DS 2 linear RGD) at the same time-point.
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supplementation with BMP-2 or other growth factors may
improve differentiation of progenitor cells, especially primary
hBMSCs, under these conditions. It is likely that the observed
difference in cell response to the different peptide sequences is
due to higher integrin binding affinity to the cyclic RGD se-
quence, preferential engagement of specific integrin receptors,
or both.43,44 Greater bond formation has been demonstrated
to enhance osteogenic differentiation of preosteoblasts en-
capsulated in RGD-presenting alginate gels and, similarly, to
drive differentiation of osteoprogenitors.45 Cyclic RGD pep-
tides are also highly selective toward the av integrin, which
regulates matrix responsiveness by activating the osteoblast-
specific transcription factor Core binding factor alpha-1=runt
related transcription factor 2 during osteogenesis.46 It is not
expected that the differences in cell response between linear
and cyclic RGD peptide–modified alginate is due to differ-
ences in coupling efficiency of the peptide to the alginate
polymer. Peptide conjugation of the linear and cyclic
RGD peptide to alginate polymer was prepared using car-
bodiimide chemistry, in which the reaction occurs between the
carboxy groups on the alginate polymer chain and the ter-
minal amine of the peptides. Because the sequence of the two
peptides is similar (linear G4RGDSP, cyclic G4CRGDSPC), it is
not anticipated that the coupling efficiencies of the two pep-
tides are significantly different. We have also confirmed that
the conjugation chemistry maintains the cyclic nature of the
cyclic RGD peptide (absence of free thiols) as assessed ac-
cording to the DTNB assay (data not shown).
Cyclic peptides, developed using cyclization of RGD pep-
tides by disulfide bonds, thioether, or rigid aromatic rings, are
more resistant to proteolysis47 and may also promote a more
stable cell-ligand bond. Enhanced integrin–adhesion ligand
binding may then promote matrix-mediated osteogenic dif-
ferentiation of hBMSCs via the extracellular signal-regulated
kinase and focal adhesion kinase signaling pathways.48 In
addition to RGD ligands, it is possible that other adhesion
ligand sequences (e.g., the synergy proline-histidine-serine-
arginine-asparagine (PHSRN) peptide) would enhance os-
FIG. 5. Proliferation and differentiation of human bone
marrow stromal cells (hBMSCs) and D1 stem cells in three-
dimensional culture using cyclic versus linear arginine-
glycine-aspartate (RGD) peptides. (A) Normalized growth
rates of D1 cells (cross-hatch) and primary hBMSCs (filled)
cultured on DS 2 linear or cyclic RGD–presenting alginate
substrates. Growth rates were calculated from cell counts
5 days postseeding and normalized by dividing the growth
rate for each cell type on cyclic RGD by the growth rate for
the same cell type cultured on gels with the same density
of linear RGD. Osteocalcin protein secretion of D1 (B) and
primary hBMSCs (C) encapsulated in DS 2 cyclic RGD–
modified alginate (triangle), DS 2 linear RGD–modified al-
ginate (diamond), or unmodified alginate (open square). D1
cells were cultured in medium supplemented with 50mg=mL
ascorbic acid and 10 mM b-glycerophosphate for osteogenic
induction at 378C and 5% carbon dioxide for 21 days. Pri-
mary hBMSCs were cultured in medium supplemented with
50 mg=mL ascorbic acid, 10 mM b-glycerophosphate, and
0.1mm dexamethasone. Values represent means and standard
deviations (n¼ 3 or 4). *p< 0.05 between noted conditions.
270 HSIONG ET AL.
teoprogenitor cell differentiation in the model sECM used in
these studies. Because the PHSRN sequence may confer in-
tegrin binding specificity49, presentation of the PHRSN with
RGD ligands may enhance a5 receptor binding and therefore
stem cell differentiation.50–52
Linear RGD densities that promoted osteogenic differenti-
ation of committed cells (MC3T3-E1 preosteoblasts) did not
induce differentiation of hBMSCs or D1 stem cells. However,
matrices presenting the higher-affinity cyclic form of this
adhesion ligand enhanced osteoprogenitor differentiation in
three dimensions. These studies indicate that the presentation
of appropriate matrix cues are critical for proliferation and
differentiation of progenitor cell populations and that bio-
material design parameters optimized for differentiated cell
types may not directly translate to stem cell populations. The
results of this study suggest that less-committed cells may
require more instruction than preosteoblasts, and this is con-
sistent with the previous findings that primary rat calvarial
osteoblasts transplanted within RGD-modified alginate ma-
trix promoted bone regeneration in vivo, whereas hBMSCs
transplanted within the same matrix did not unless provided
with additional cues.16,17 In future studies, it would be inter-
esting to further investigate whether the presentation of
cyclic RGD peptides similarly enhance the differentiation of
hBMSCs toward chondrocytes, adipocytes, or other differen-
tiated cell types. It is likely that design of sECMs tailored to
promote stem cell differentiation may enhance tissue regen-
eration by transplanted cells and may even reduce the need
for exogenous growth factors.
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